Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/43064
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorBaena Pineda, Ana Yulied-
dc.contributor.authorBocanegra García, Orfa Yamile-
dc.contributor.authorLopera Restrepo, Francisco Javier-
dc.contributor.authorVila Castelar, Clara-
dc.contributor.authorMuñoz, Nathalia-
dc.contributor.authorPapp, Kathryn V.-
dc.contributor.authorAmariglio, Rebecca E.-
dc.contributor.authorGuzmán Vélez, Edmarie-
dc.contributor.authorSánchez, Justin S.-
dc.contributor.authorReiman, Eric M.-
dc.contributor.authorJohnson, Keith A.-
dc.contributor.authorSperling, Reisa A.-
dc.contributor.authorRentz, Dorene M.-
dc.contributor.authorQuiroz Gaviria, Yakeel Tatiana-
dc.date.accessioned2024-11-02T23:50:27Z-
dc.date.available2024-11-02T23:50:27Z-
dc.date.issued2020-
dc.identifier.citationVila-Castelar C, Muñoz N, Papp KV, Amariglio RE, Baena A, Guzmán-Vélez E, Bocanegra Y, Sanchez JS, Reiman EM, Johnson KA, Sperling RA, Lopera F, Rentz DM, Quiroz YT. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 Sep 10;12(1):104. doi: 10.1186/s13195-020-00671-w.spa
dc.identifier.urihttps://hdl.handle.net/10495/43064-
dc.description.abstractABSTRACT: Background: To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzheimer's disease mutation (E280A) in Presenilin-1, who are genetically determined to develop early-onset dementia, from matched non-carriers. We also sought to examine whether LAS-FNAME performance is associated with amyloid-β and regional tau burden in mutation carriers. Methods: A total of 35 cognitively intact mutation carriers (age range 26-41), 19 symptomatic carriers, and 48 matched non-carriers (age range 27-44) completed a neuropsychological assessment including the LAS-FNAME. A subset of participants (31 carriers [12 symptomatic] and 35 non-carriers) traveled from Colombia to Boston to undergo positron emission tomography (PET) using Pittsburgh compound B to measure mean cortical amyloid-β and flortaucipir for regional tau. ANOVA analyses and Spearman correlations were used to examine group differences and relationships among LAS-FNAME performance and amyloid-β and tau accumulation. Results: Compared to non-carriers, cognitively intact mutation carriers had lower scores on the LAS-FNAME Total Scores (p = .040). Across all carriers (including symptomatic carriers), higher levels of amyloid-β (r = - .436, p = .018) and regional tau in the entorhinal (r = - .394, p = .031) and inferior temporal cortex (r = - .563, p = .001) were associated with lower LAS-FNAME Total Scores. Conclusions: Performance on the LAS-FNAME differentiated between cognitively intact mutation carriers from non-carriers and was associated with greater amyloid and tau burden when examining all carriers. Findings suggest that the LAS-FNAME is sensitive to early clinical and pathological changes and can potentially help track disease progression in Spanish-speaking individuals. Keywords: Alzheimer’s disease; Associative memory; Autosomal dominant Alzheimer’s disease; Imaging; Neuropsychology; PET.spa
dc.format.extent11 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherBMC (BioMed Central)spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleThe Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's diseasespa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Neurociencias de Antioquiaspa
dc.publisher.groupGrupo Neuropsicología y Conductaspa
dc.identifier.doi10.1186/s13195-020-00671-w-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1758-9193-
oaire.citationtitleAlzheimer's Research and Therapyspa
oaire.citationstartpage1spa
oaire.citationendpage11spa
oaire.citationvolume12spa
oaire.citationissue1spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
oaire.fundernameNational Institutes of Healthspa
dc.publisher.placeLondres, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAlzheimer Disease-
dc.subject.decsEnfermedad de Alzheimer-
dc.subject.decsCognition-
dc.subject.decsCognición-
dc.subject.decsPositron-Emission Tomography-
dc.subject.decsTomografía de Emisión de Positrones-
dc.subject.decsPresenilin-1-
dc.subject.decsPresenilina-1-
oaire.funderidentifier.crossreffunderRoR:01cwqze88-
dc.description.researchgroupidCOL0010744spa
dc.description.researchgroupidCOL0007551spa
oaire.awardnumberR01 AG054671/AG/NIA NIH HHS/United Statesspa
oaire.awardnumberDP5 OD019833/OD/NIH HHS/United Statesspa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D053764-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000544-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D003071-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D049268-
dc.relation.ispartofjournalabbrevAlzheimers. Res. Ther.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
BaenaAna_2020_Associative_Memory_Exam.pdfArtículo de investigación2.75 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons